SCHEMBL3663945

SCHEMBL3663945

CSc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 13/20 0.68
CSNK1D P48730 13/20 0.68
MAP4K4 O95819 12/20 0.68
CSNK1A1 P48729 12/20 0.68
PRKD3 O94806 11/20 0.68
MINK1 Q8N4C8 11/20 0.68
MAPK8 P45983 9/20 0.68
CSNK1G3 Q9Y6M4 8/20 0.68
CSNK1G2 P78368 8/20 0.68
GSK3B P49841 7/20 0.68
CSNK1E P49674 3/20 0.52
CCNA2 P20248 2/20 0.52
CDK2 P24941 2/20 0.52
CDK5 Q00535 2/20 0.52
CDK5R1 Q15078 2/20 0.52
TAOK1 Q7L7X3 8/20 0.51
MAP4K5 Q9Y4K4 7/20 0.51
LIMK1 P53667 5/20 0.51
CLK4 Q9HAZ1 3/20 0.51
MAPK1 P28482 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923880 0.89 MAPK9 (0.67) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL3522761 0.87 CSNK1E (0.69) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL3524337 0.84 MAPK9 (0.66) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL3525735 0.83 MAPK9 (0.63) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL3663739 0.81 MAPK9 (1.00) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL3522704 0.76 CDK2 (0.49) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL4300868 0.75 MAP4K4 (0.55) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL3725128 0.74 MAPK9 (0.64) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL3521273 0.71 MAPK9 (0.62) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3
SCHEMBL3724163 0.71 MAPK9 (1.00) MAPK9CSNK1DMAP4K4CSNK1A1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139329-A1 NOVEL IMIDAZO BASED HETEROCYCLES Abbott Laboratories (US) 2010-01-06 EP disclosed
US-20080249305-A1 Novel imidazole based heterocycles ABBOTT LABORATORIES 2008-10-09 US disclosed
US-20080249305-A1 Novel imidazole based heterocycles ABBOTT LABORATORIES 2008-10-09 US disclosed
US-20080249305-A1 Novel imidazole based heterocycles ABBOTT LABORATORIES 2008-10-09 US disclosed
US-20080242862-A1 Novel imidazo based heterocycles ABBOTT LABORATORIES 2008-10-02 US disclosed
US-20080242862-A1 Novel imidazo based heterocycles ABBOTT LABORATORIES 2008-10-02 US disclosed
US-20080242862-A1 Novel imidazo based heterocycles ABBOTT LABORATORIES 2008-10-02 US disclosed
WO-2008118485-A1 NOVEL IMIDAZO BASED HETEROCYCLES ABBOTT LABORATORIES (US) 2008-10-02 WO disclosed
WO-2008118485-A1 NOVEL IMIDAZO BASED HETEROCYCLES ABBOTT LABORATORIES (US) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242862-A1 Novel imidazo based heterocycles CDK4, CDK2, MAP3K15 MAPK9 274/4885CSNK1D 669/4885MAP4K4 22/4885
US-20080249305-A1 Novel imidazole based heterocycles MAP3K5, MAP3K15, MAP3K20 MAPK9 249/4885CSNK1D 743/4885MAP4K4 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.